Recent Quotes (30 days)

You have no recent quotes
chg | %

R.E.A. Holdings plc news

   Watch this stock
Showing stories 1 - 1 of about 1   

Articles published

RE.B 84.50 -2.25 (-2.59%)
price chart
Six-Year Follow-Up Data for SPRYCEL� (dasatinib) 100 mg Once Daily ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL� (dasatinib) in Philadelphia ...